Geron (GERN) Share-based Compensation Growth (1y) (2011 - 2026)
Powered by 
Analysis
Geron (GERN) Share-based Compensation Growth (1y) (2011 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 19.90% |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 2.67% |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 71.86% |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | -3.46% |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -7.69% |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | -22.43% |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 3.34% |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | Geron | 914.60 Mn | 613.75 Mn | - | -26.83% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -26.83% |
| Mar 31, 2026 | -33.81% |
| Dec 31, 2025 | -15.04% |
| Sep 30, 2025 | -2.74% |
| Jun 30, 2025 | -58.69% |
| Mar 31, 2025 | 52.20% |
| Dec 31, 2024 | 53.83% |
| Sep 30, 2024 | -4.36% |
| Jun 30, 2024 | 2,757.42% |
| Mar 31, 2024 | -38.07% |
| Dec 31, 2023 | 101.83% |
| Sep 30, 2023 | 249.20% |
| Jun 30, 2023 | -24.70% |
| Mar 31, 2023 | 365.43% |
| Dec 31, 2022 | -5.08% |
| Sep 30, 2022 | 2.74% |
| Jun 30, 2022 | 306.95% |
| Mar 31, 2022 | 9,852.94% |
| Dec 31, 2021 | 24.46% |
| Sep 30, 2021 | 13.57% |